A new study in Clinical Epidemiology and Global Health features the Glivec®Patient Assistance Program (GIPAP) and reveals that “chronic myelocytic leukemia (CML) is diagnosed at an earlier age in poorer populations than in more affluent populations.” The study focused on India’s CML population to investigate other possible contributors to early age at onset. The team of authors include our very own South Asia Region Head Viji Venkatesh, and Max CEO Pat Garcia-Gonzalez, as well as Paul H. Levine, Kunal Ajmera, Brenna O’Neill, Heather J. Hoffman.
The study is only available to the public for a limited time so if you know a physician or researcher that would benefit from this study, share it today!
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
For many patients, there aren’t many opportunities for them to learn about their disease directly from experts. So when the opportunity to hear from a hematologist at Naresuan University Hospital in Thailand, we were excited to maximize the event.
How we continue providing emotional support for people facing cancer throughout COVID-19
Every year our South Asia team organizes 15–20 meetings that unite hundreds of the patients we serve, their families, caregivers, and physicians. These meetings provide a safe and comfortable platform for everyone to share their insights and learn from each other’s experiences with cancer.
